Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib adjuvant therapy after resection for high-risk hepatocellular carcinoma
ChiCTR2500097924Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Relapse-free survival. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500097924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097924.